Deciphera Pharmaceuticals... (DCPH)
Deciphera Pharmaceuticals Statistics
Share Statistics
Deciphera Pharmaceuticals has 86.48M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 86.48M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 46.43M |
| Failed to Deliver (FTD) Shares | 1.3K |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 3.17M, so 3.67% of the outstanding shares have been sold short.
| Short Interest | 3.17M |
| Short % of Shares Out | 3.67% |
| Short % of Float | 5.12% |
| Short Ratio (days to cover) | 2.79 |
Valuation Ratios
The PE ratio is null and the forward PE ratio is null.
| PE Ratio | null |
| Forward PE | n/a |
| PS Ratio | null |
| Forward PS | null |
| PB Ratio | null |
| P/FCF Ratio | null |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Deciphera Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of null, with a Debt / Equity ratio of null.
| Current Ratio | null |
| Quick Ratio | null |
| Debt / Equity | null |
| Debt / EBITDA | - |
| Debt / FCF | - |
| Interest Coverage | null |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | 355 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | - |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by 74.44% in the last 52 weeks. The beta is 0.18, so Deciphera Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.18 |
| 52-Week Price Change | 74.44% |
| 50-Day Moving Average | 21.46 |
| 200-Day Moving Average | 15.86 |
| Relative Strength Index (RSI) | 85.58 |
| Average Volume (20 Days) | 1.87M |
Income Statement
| Revenue | n/a |
| Gross Profit | - |
| Operating Income | - |
| Net Income | - |
| EBITDA | - |
| EBIT | n/a |
| Earnings Per Share (EPS) | null |
Balance Sheet
The company has - in cash and - in debt, giving a net cash position of 0.
| Cash & Cash Equivalents | - |
| Total Debt | - |
| Net Cash | 0 |
| Retained Earnings | - |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was - and capital expenditures -, giving a free cash flow of -.
| Operating Cash Flow | - |
| Capital Expenditures | - |
| Free Cash Flow | - |
| FCF Per Share | null |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DCPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for DCPH.
| Price Target | $25.6 |
| Price Target Difference | 0% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |